ImmunityBio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ImmunityBio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-25.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 61% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$58Sales grew 47,103% in 3 years; of every extra $100 of sales, $58 became extra profit.
Higher than 72% of Healthcare companies in United States.
Asset Productivity Ratio
+47103% / +39%In 3 years sales changed by +47103% while total assets changed by +39%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-40.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 68% of Healthcare companies in United States.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 72% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 81% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
ImmunityBio, Inc. made a loss over the last year. ImmunityBio, Inc. owes $2.66 for every $1 it owns. ImmunityBio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossImmunityBio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-8.41ImmunityBio, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$8.8 BThe total market value of all of ImmunityBio, Inc.'s shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeImmunityBio, Inc.'s net worth is negative ($1.0 B below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
2.66×ImmunityBio, Inc. owes $2.66 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Dividend yield
NoneImmunityBio, Inc. does not currently pay a dividend.
Revenue growth
+668%Revenue rose 668% in the year to Dec 2025, and grew 679% a year on average over 3 years.
Profit growth
LossImmunityBio, Inc. made a loss in each of the last two years.
Profit margin
-310.2%ImmunityBio, Inc. lost $310 for every $100 of revenue.
Interest cover
Not coveredImmunityBio, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtImmunityBio, Inc. had $275 M more debt than cash (net debt) at Dec 2025.
Questions
How much does ImmunityBio, Inc. owe compared with what it owns?
ImmunityBio, Inc. owes $2.66 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Does ImmunityBio, Inc. pay a dividend?
No. ImmunityBio, Inc. does not currently pay a dividend.
Is ImmunityBio, Inc.'s revenue growing?
Revenue rose 668% in the year to Dec 2025, and grew 679% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.